Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience.

Journal of ophthalmic inflammation and infection·2024

Same author

Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology.

Ophthalmology and therapy·2022

Same author

Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.

PloS one·2021

Same author

The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings.

Ocular immunology and inflammation·2020

Same author

Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop.

Ocular immunology and inflammation·2019

Same author

Ultra-wide-Field Fundus Autofluorescence for the Detection of Inherited Retinal Disease in Difficult-to-Examine Children.

Journal of pediatric ophthalmology and strabismus·2019

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Refractory necrotizing scleritis successfully treated with adalimumab.

Lola E Lawuyi¹, Avinash Gurbaxani²

¹, Gate 17, Villa 970 Al Raha Gardens, Abu Dhabi, United Arab Emirates. Lola27law@yahoo.co.uk.

Journal of Ophthalmic Inflammation and Infection

|October 14, 2016

Summary

Necrotizing scleritis, a severe eye condition, was successfully treated in two patients using adalimumab, a biologic medication targeting inflammation. This offers a potential new treatment avenue for this destructive disease.

Keywords:

Adalimumab Necrotizing scleritis TNF inhibitors

More Related Videos

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Published on: September 11, 2013

Related Experiment Videos

Last Updated: Mar 13, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Iris Fixation via External Pentagram Suturing

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate

Published on: September 11, 2013

Area of Science:

Ophthalmology
Rheumatology
Immunology

Background:

Necrotizing scleritis is a severe, destructive ocular condition with significant vision-threatening potential.
It encompasses forms with and without inflammation, including scleromalacia perforans.
Adalimumab, a biologic agent, targets tumor necrosis factor (TNF) and is approved for various autoimmune conditions.

Discussion:

This report details two successful cases of necrotizing scleritis managed with adalimumab.
The use of adalimumab in necrotizing scleritis demonstrates its potential efficacy beyond its approved indications.
Tumor necrosis factor inhibition may be a viable therapeutic strategy for severe, destructive forms of scleritis.

Key Insights:

Successful treatment of two necrotizing scleritis cases using adalimumab.
Adalimumab, a TNF inhibitor, shows promise in managing severe ocular inflammatory disease.
This suggests a potential role for targeted biologic therapy in sight-threatening scleritis.

Outlook:

Further investigation into adalimumab's efficacy and safety for necrotizing scleritis is warranted.
Exploring TNF inhibition as a treatment for similar destructive inflammatory eye conditions.
Potential for improved patient outcomes in severe scleritis through targeted biologic therapies.